Dear Dr. Roach: I am 85 and healthy apart from polycythemia vera, for which I take aspirin. I was interested in the new blood test for cancer. Is it worthwhile? Dear M.N.: When screening patients for ...

DEAR DR. ROACH: I am 85 and healthy apart from polycythemia vera, for which I take aspirin. I was interested in the new blood test for cancer. Is it worthwhile? -- M.N. ANSWER: When screening patients ...

Please provide your email address to receive an email when new articles are posted on . Cell-free fetal antigen analyses had 100% consistency for 465 calls on antigens in which women were ...

The multi-modal approach leverages additional information from the patient's tumor sample, using Natera's AI models trained on long-term molecular and clinical outcomes from Natera's proprietary ...

Small cell lung cancer (SCLC) remains a challenging cancer type to treat effectively. While patients initially respond to chemotherapy and immunotherapies, the disease almost always returns, often ...

Please provide your email address to receive an email when new articles are posted on . Biopsies with high donor-derived cell-free DNA levels were likely to reveal antibody-mediated rejection.

Pediatric ENT infections are prevalent and one of the most common reasons for antibiotic prescriptions. Turnaround times of conventional culturing assays are long leading to poor clinical management ...

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) testing, today announced that it has received commercial insurance coverage for its Prospera Heart ...

Explore the benefits of prenatal DNA screening to detect cytomegalovirus in early pregnancy for better health decisions.

Natera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA testing and precision medicine, today announced a new collaboration with NVIDIA to accelerate the development of Natera’s multimodal AI ...